Scholar Rock Holding's revenue per share for the
three
months ended in Sep. 2024 was $0.00.
Scholar Rock Holding's revenue per share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Scholar Rock Holding's Revenue per Share or its related term are showing as below:
During the past 8 years, Scholar Rock Holding's highest 3-Year average Revenue Per Share Growth Rate was 228.40% per year. The lowest was -9.20% per year. And the median was 109.60% per year.
SRRK's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.5 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
Scholar Rock Holding Revenue per Share Historical Data
The historical data trend for Scholar Rock Holding's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Scholar Rock Holding's Revenue per Share
For the Biotechnology subindustry, Scholar Rock Holding's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scholar Rock Holding's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's PS Ratio distribution charts can be found below:
* The bar in red indicates where Scholar Rock Holding's PS Ratio falls into.
Scholar Rock Holding Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Scholar Rock Holding's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scholar Rock Holding (NAS:SRRK) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Scholar Rock Holding Revenue per Share Related Terms
Thank you for viewing the detailed overview of Scholar Rock Holding's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF?1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRRK has been successfully added to your 